Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis. / Makshakov, Gleb; Magonov, Evgeniy; Totolyan, Natalia; Nazarov, Vladimir; Lapin, Sergey; Mazing, Alexandra; Verbitskaya, Elena; Trofimova, Tatiana; Krasnov, Vladimir; Shumilina, Maria; Skoromets, Alexander; Evdoshenko, Evgeniy.
In: Neurology Research International, Vol. 2017, 8652463, 01.01.2017.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis
AU - Makshakov, Gleb
AU - Magonov, Evgeniy
AU - Totolyan, Natalia
AU - Nazarov, Vladimir
AU - Lapin, Sergey
AU - Mazing, Alexandra
AU - Verbitskaya, Elena
AU - Trofimova, Tatiana
AU - Krasnov, Vladimir
AU - Shumilina, Maria
AU - Skoromets, Alexander
AU - Evdoshenko, Evgeniy
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE were detected with a 3 Tesla scanner on postcontrast fluid-Attenuated inversion-recovery (FLAIR) sequence. Expanded Disability Status Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1 weighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease duration (p=0,0098) and higher EDSS score (p=0,039), but not a higher relapse rate (p=0,091). No association of LMCE with higher frequency of contrast-enhancing lesions on T1-weighted images was detected (p=0,3842). Analysis of covariates, adjusted for age, sex, and disease duration, revealed a significant effect of LMCE on the cortex volume (p=0.043, F=2.529), the total grey matter volume (p=0.043, F=2.54), and total ventricular volume (p=0.039, F=2.605). Conclusions. LMCE was shown to be an independent and significant biomarker of grey matter atrophy and disability in MS.
AB - Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE were detected with a 3 Tesla scanner on postcontrast fluid-Attenuated inversion-recovery (FLAIR) sequence. Expanded Disability Status Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1 weighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease duration (p=0,0098) and higher EDSS score (p=0,039), but not a higher relapse rate (p=0,091). No association of LMCE with higher frequency of contrast-enhancing lesions on T1-weighted images was detected (p=0,3842). Analysis of covariates, adjusted for age, sex, and disease duration, revealed a significant effect of LMCE on the cortex volume (p=0.043, F=2.529), the total grey matter volume (p=0.043, F=2.54), and total ventricular volume (p=0.039, F=2.605). Conclusions. LMCE was shown to be an independent and significant biomarker of grey matter atrophy and disability in MS.
UR - http://www.scopus.com/inward/record.url?scp=85031911300&partnerID=8YFLogxK
U2 - 10.1155/2017/8652463
DO - 10.1155/2017/8652463
M3 - Article
AN - SCOPUS:85031911300
VL - 2017
JO - Neurology Research International
JF - Neurology Research International
SN - 2090-1852
M1 - 8652463
ER -
ID: 34717662